Le Lézard
Classified in: Health
Subject: SVY

The conjunctivitis therapeutics market will register a CAGR of over 8% by 2023


NEW YORK, Feb. 11, 2019 /PRNewswire/ -- About this market
Conjunctivitis is inflammation in the inside of the eyelids and the covering of the white of the eye, which causes the conjunctival blood vessels to dilate. While allergic conjunctivitis is known to be prevalent among people with allergies, infectious conjunctivitis is known to spread at a very fast rate. The ease of availability of antibiotic eye drops and ointments for the treatment of bacterial conjunctivitis and antibiotics for viral conjunctivitis is leading to an increase in the use of these therapeutics. The use of therapeutics is primarily to avoid the progression of the disease into severe indications, which could increase the economic burden of patients. Hence, the infectious nature of the disease is expected to increase the adoption rate of therapeutics, thus resulting in the growth of the market during the forecast period. Technavio's analysts have predicted that the conjunctivitis therapeutics market will register a CAGR of over 8% by 2023.

Read the full report: https://www.reportlinker.com/p05734247

Market Overview
Growing allergy cases
Allergic conjunctivitis is caused by various types of allergies such as hay fever and asthma. Being allergic to substances such as dust mites and mold can also increase the risk of infection. Globally. the prevalence of various types of allergies has been growing at a significant rate. The increasing prevalence of allergies such as dust mite allergy and pollen allergy increase the risk of allergic conjunctivitis.
Patent cliff
One of the major challenges faced by the global conjunctivitis therapeutics market is the patent expiration of various drugs in the market. Patent expiration leads to the increasing launch of generic drugs, thereby leading to value erosion of the global market. The patent expiry of blockbuster drugs also impacts the sales of the vendors significantly, making it difficult for vendors to compete in the market. Thus, the patent expiry of blockbuster drugs and the subsequent entry of generics restrict market growth.
For the detailed list of factors that will drive and challenge the growth of the conjunctivitis therapeutics market during the 2019-2023, view our report.

Competitive Landscape
The market appears to be concentrated and with the presence of very few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Read the full report: https://www.reportlinker.com/p05734247

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 18:14
George Michael Varkarakis, MD is recognized by Continental Who's Who in the field of Medicine as a Plastic & Reconstructive Surgeon at his Private Practice.    With over 21 years of experience in his field, Dr. George M. Varkarakis is an...

at 17:45
Arvato has launched an automated platform that supports health insurance companies in producing their CMS-regulated Annual Notice of Change (ANOC) and Evidence of Coverage (EOC) documents. The platform manages the work stream from data input and...

at 17:45
Today the National Kidney Registry was presented with the 2019 American Society of Transplantation Innovation Award at the Cutting Edge of Transplantation Summit in Phoenix, Arizona. The AST Innovation Award was created to showcase a project or...

at 17:30
Neovasc Inc. ("Neovasc" or the "Company") wishes to advise that it has filed the following amendments, which documents are publicly available on SEDAR at www.sedar.com: unaudited amended and restated condensed interim financial statements for the...

at 17:25
Urovant Sciences , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it has entered into a debt financing agreement with Hercules...

at 17:20
Sinovac Biotech Ltd. ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its Board of Directors (the "Board") determined that certain stockholders became "Acquiring...



News published on 11 february 2019 at 20:05 and distributed by: